Why the study?
Does dual antiplatelet therapy for ≤6 months reduce bleeding events without increasing mortality or ischemic outcomes compared to 12-month therapy in patients after PCI with DES?
Does dual antiplatelet therapy for ≤6 months reduce bleeding events without increasing mortality or ischemic outcomes compared to 12-month therapy in patients after PCI with DES?
Short-term DAPT (≤6 months) reduces bleeding risk without compromising ischemic or mortality outcomes compared to standard 12-month DAPT after DES implantation.
Answers are grounded in this paper and cite their sources.
May support ≤6-month DAPT post-DES PCI to cut bleeding; challenges prior 12-month standard.
DAPT for ≤6 months is associated with similar mortality and ischemic outcomes but less bleeding events compared with 12-month DAPT after PCI with DES.
No takes yet. Share an insight, caveat, or question.
Villablanca et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: